Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C., 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2007

EXELIXIS, INC.

(Exact Name of Registrant as Specified in its Charter)

Commission File Number: 0-30235

 

Delaware   04-3257395
(State or Other Jurisdiction of   (I.R.S. Employer
Incorporation or Organization)   Identification No.)

170 Harbor Way

P.O. Box 511

South San Francisco, California 94083-0511

(Address of Principal Executive Offices, Including Zip Code)

(650) 837-7000

(Registrant’s Telephone Number, Including Area Code)

 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Items to be Included in this Report

 

Item 7.01 Regulation FD Disclosure

Exelixis, Inc. (the “Company”) is correcting a slide that was presented at the Company’s R&D Day held on December 5, 2007 in New York, New York and that was made available on the Company’s web site in connection therewith. The reference to the Company’s compound XL880 under the heading “Three POC compounds presented to GSK” on slide 235 should read as follows: “XL880 – decision by mid-December”. A corrected version of the presentation is available on the Company’s web site at www.exelixis.com.

Signature(s)

Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.

 

        EXELIXIS, INC.
Date: December 6, 2007     By:  

/s/ James B. Bucher

        James B. Bucher
        Vice President, Corporate Legal Affairs and Secretary